GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

mepolizumab   Click here for help

GtoPdb Ligand ID: 7685

Synonyms: Nucala® | SB-240563
Approved drug Immunopharmacology Ligand
mepolizumab is an approved drug (EMA & FDA (2015))
Compound class: Antibody
Comment: The Nucala® brand of mepolizumab is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: mepolizumab

Bioactivity Comments
In monkey studies mepolizumab decreased eosinophil count with an IC50 of 1.43 μg/ml, and exhibited a half-life of ~14.5 days [9].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-5 Primary target of this compound Hs Antibody Binding 11.4 pKd - 5
⤷ pKd 11.4 (Kd 4.2x10-12 M) [5]
Description: Binding affinity for recombinant human IL-5.